Skip to main content
Landing Pages / Profile
Photo of  Michael E. Luggen, MD

Michael E. Luggen, MD

Professor-Emeritus

Internal Medicine | College of Medicine

Education/Credentials
  • Fellowship: University of Cincinnati (Division of Immunology )
  • Residency : University of Cincinnati (Internal Medicine)
  • Medical Degree: Columbia University
  • Bachelor's Degree: Dartmouth Medical School (Biomedical Science )
  • Bachelor's Degree: Harvard College
Board Certifications & Licenses

American Board of Internal Medicine (Certification Date: 1978-09-13)
American Board of Internal Medicine (Rheumatology) (Certification Date: 1982-11-09)

Specialties

Internal Medicine
Rheumatology

Contact Information
Research Interests

Evaluation of New Therapies for RA and Epidemiologic Studies on the Influence of Race on Outcome of RA.

Clinical Interests

Rheumatology

Ankylosing Spondylitis

Autoimmune Vasculitis

Behcet Syndrome (Neuro-Bechet)

Central Nervous System Lupus Vasculitis

Collagen Disease

CREST Syndrome

Cryoglobulinemia

Cutaneous, Leukocytoclastic, Vasculitis

Gout

Hip Rheumatoid Arthritis

Lupus (Systemic lupus erythematosus)

Lupus Erythematosus Panniculitis

Lupus Nephritis

Microscopic Polyangiitis

Mixed Connective Tissue Disease (MCTD)

Osteochondritis Dissecans

Overlap Connective Tissue Disease

Paget Disease

Polymyalgia Rheumatica

Polymyositis

Polymyositis/Dermatomyositis

Pseudogout

Psoriatic Arthritis

Raynaud Phenomenon in Scleroderma

Raynaud's Disease

Reactive Arthritis (Reiter's Syndrome)

Rheumatoid Arthritis

Rheumatoid Vasculitis

Still's Disease

Systemic Lupus Erythematosus (SLE)

Systemic Vasculitis

Takayasu Arteritis

Temporal Arteritis (Giant cell arteritis)

Vasculitis (Angiitis)

Weill-Marchesani Syndrome

Peer Reviewed Publications

Chalhoub, N E; Luggen, M E 2019. Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly. Lupus, 28 1, 51-58

Gulati, Gaurav; Iffland, Philip H; Janigro, Damir; Zhang, Bin; Luggen, Michael E 2016. Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction. Clinical rheumatology, 35 12, 2989-2997

Luggen, Michael E; Gulati, Gaurav; Zhang, Bin; Willis, Rohan A; Gonzalez, Emilio B 2016. Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. Clinical rheumatology, 35 1, 93-9

Antonchak, Marc A; Saoudian, Mahnaz; Khan, Amber R; Brunner, Hermine I; Luggen, Michael E 2011. Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study. The Journal of rheumatology, 38 6, 1020-5

Wasko, Mary Chester M; Hubert, Helen B; Lingala, Vijaya Bharathi; Elliott, Jennifer R; Luggen, Michael E; Fries, James F; Ward, Michael M 2007. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA, 298 2, 187-93

Kremer, Joel M; Genovese, Mark C; Cannon, Grant W; Caldwell, Jacques R; Cush, John J; Furst, Daniel E; Luggen, Michael E; Keystone, Ed; Weisman, Michael H; Bensen, William M; Kaine, Jeffrey L; Ruderman, Eric M; Coleman, Patricia; Curtis, David L; Kopp, Elliot J; Kantor, Seth M; Waltuck, Jonathan; Lindsley, Herbert B; Markenson, Joseph A; Strand, Vibeke; Crawford, Bruce; Fernando, Indra; Simpson, Karen; Bathon, Joan M 2002. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 137 9, 726-33

Mould, D R; Davis, C B; Minthorn, E A; Kwok, D C; Elliott, M J; Luggen, M E; Totoritis, M C 1999. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clinical pharmacology and therapeutics, 66 3, 246-57

Williams, H J; Alarcon, G S; Joks, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; St Clair, E W; Willkens, R F; Yarboro, C; Morgan, J G; Egger, M J; Ward, J R 1999. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. The Journal of rheumatology, 26 4, 816-25

Williams, H J; Alarcón, G S; Neuner, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; Polisson, R P; Willkens, R F; Yarboro, C; Morgan, J; Egger, M J; Ward, J R 1998. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. The Journal of rheumatology, 25 2, 261-8

Alarcón, G S; Willkens, R F; Ward, J R; Clegg, D O; Morgan, J G; Ma, K N; Singer, J Z; Steen, V D; Paulus, H E; Luggen, M E; Polisson, R P; Ziminski, C M; Yarboro, C; Williams, H J 1996. Early undifferentiated connective tissue disease. IV.Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline. Arthritis and rheumatism, 39 3, 403-14

Clegg, D O; Reda, D J; Mejias, E; Cannon, G W; Weisman, M H; Taylor, T; Budiman-Mak, E; Blackburn, W D; Vasey, F B; Mahowald, M L; Cush, J J; Schumacher, H R; Silverman, S L; Alepa, F P; Luggen, M E; Cohen, M R; Makkena, R; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G 1996. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism, 39 12, 2013-20

Clegg, D O; Reda, D J; Weisman, M H; Blackburn, W D; Cush, J J; Cannon, G W; Mahowald, M L; Schumacher, H R; Taylor, T; Budiman-Mak, E; Cohen, M R; Vasey, F B; Luggen, M E; Mejias, E; Silverman, S L; Makkena, R; Alepa, F P; Buxbaum, J; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G 1996. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism, 39 12, 2004-12

Luggen, M E 1994. [Duration of use of non-steroidal anti-inflammatory agents in patients with rheumatoid arthritis]. Revue du rhumatisme (Ed. francaise : 1993), 61 10 Pt 2, 165S-172S

Bulpitt, K J; Clements, P J; Lachenbruch, P A; Paulus, H E; Peter, J B; Agopian, M S; Singer, J Z; Steen, V D; Clegg, D O; Ziminski, C M; Alarcon, G S; Luggen, M E; Polisson, R P; Willkens, R F; Reading, J C; Williams, H J; Ward, J R 1993. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Annals of internal medicine, 118 8, 602-9

Alarcón, G S; Williams, G V; Singer, J Z; Steen, V D; Clegg, D O; Paulus, H E; Billingsley, L M; Luggen, M E; Polisson, R P; Willkens, R F 1991. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. The Journal of rheumatology, 18 9, 1332-9

Clegg, D O; Williams, H J; Singer, J Z; Steen, V D; Schlegel, S; Ziminski, C; Alarcón, G S; Luggen, M E; Polisson, R P; Willkens, R F 1991. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. The Journal of rheumatology, 18 9, 1340-3

Bendon, R W; Hayden, L E; Hurtubise, P E; Getahun, B; Siddiqi, T A; Glueck, H I; Luggen, M E; Gartside, P S 1990. Prenatal screening for anticardiolipin antibody. American journal of perinatology, 7 3, 245-50

Fritz, D A; Luggen, M E; Hess, E V 1989. Unusual longevity in primary systemic amyloidosis: a 19-year survivor. The American journal of medicine, 86 2, 245-8

Hess, E V; Luggen, M E 1989. Remodeling the pyramid--a concept whose time has not yet come. The Journal of rheumatology, 16 9, 1175-6

Luggen, M E; Gartside, P S; Hess, E V 1989. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. The Journal of rheumatology, 16 12, 1565-9

Williams, H J; Ward, J R; Dahl, S L; Clegg, D O; Willkens, R F; Oglesby, T; Weisman, M H; Schlegel, S; Michaels, R M; Luggen, M E 1988. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis and rheumatism, 31 6, 702-13

Alarcón, G S; Billingsley, L M; Clegg, D O; Hardin, J G; Klippel, J; Luggen, M E; Polisson, R P; Singer, J Z; Szydlo, L; Willkens, R F 1987. Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and rheumatism, 30 2, 218-20

Thun, M; Tanaka, S; Smith, A B; Halperin, W E; Lee, S T; Luggen, M E; Hess, E V 1987. Morbidity from repetitive knee trauma in carpet and floor layers. British journal of industrial medicine, 44 9, 611-20

Tanaka, S; Halperin, W E; Smith, A B; Lee, S T; Luggen, M E; Hess, E V 1985. Skin effects of occupational kneeling. American journal of industrial medicine, 8 4-5, 341-9

Williams, H J; Willkens, R F; Samuelson, C O; Alarcón, G S; Guttadauria, M; Yarboro, C; Polisson, R P; Weiner, S R; Luggen, M E; Billingsley, L M 1985. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and rheumatism, 28 7, 721-30

Stewart, J; Luggen, M E; Valtin, H 1972. A computer model of the renal countercurrent system. Kidney international, 2 5, 253-63

Kocharla L.;Taylor J.;Weiler T.;Ting T.;Luggen M.;Brunner H. 12-01-2009. Monitoring methotrexate toxicity in juvenile idiopathic arthritis Journal of Rheumatology, 36 12, 2813-2818

Wasko M.;Hubert H.;Lingala V.;Elliott J.;Luggen M.;Fries J.;Ward M. 11-28-2007. Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine: Reply [5] Journal of the American Medical Association, 298 20, 2369-2370

Ahmed M.;Luggen M.;Herman J.;Weiss K.;Decourten-Myers G.;Quinlan J.;Khanna D. 11-01-2006. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration Journal of Rheumatology, 33 11, 2344-2346

Adhikari T.;Piatti A.;Luggen M. 10-01-2011. Cognitive dysfunction in SLE: Development of a screening tool Lupus, 20 11, 1142-1146

Genovese M.C.;Becker J.C.;Schiff M.;Luggen M.;Sherrer Y.;Kremer J.;Birbara C.;Box J.;Natarajan K.;Nuamah I.;Li T.;Aranda R.;Hagerty D.T.;Dougados M. 09-15-2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor ? inhibition New England Journal of Medicine, 353 11, 1114-1123

Genovese M.C.;Schiff M.;Luggen M.;Le Bars M.;Aranda R.;Elegbe A.;Dougados M. 08-01-2012. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid a Journal of Rheumatology, 39 8, 1546-1554

Kremer J.;Genovese M.;Cannon G.W.;Caldwell J.;Cush J.;Furst D.E.;Luggen M.;Keystone E.;Bathon J.;Kavanaugh A.;Ruderman E.;Coleman P.;Curtis D.;Kopp E.;Kantor S.;Weisman M.;Waltuck J.;Lindsley H.B.;Markenson J.;Crawford B.;Fernando I.;Simpson K.;Strand V. 08-01-2004. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis Journal of Rheumatology, 31 8, 1521-1531

Moreland L.W.;Alten R.;Van Den Bosch F.;Appelboom T.;Leon M.;Emery P.;Cohen S.;Luggen M.;Shergy W.;Nuamah I.;Becker J.C. 06-22-2002. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, p Arthritis and Rheumatism, 46 6, 1470-1479

Keystone E.;Kremer J.;Russell A.;Box J.;Abud-Mendoza C.;Elizondo M.;Luo A.;Aranda R.;Delaet I.;Swanink R.;Gujrathi S.;Luggen M. 06-01-2012. Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase II Annals of the Rheumatic Diseases, 71 6, 857-861

Vincenti F.;Luggen M. 05-11-2007. T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and Annual Review of Medicine, 58 , 347-358

Genovese M.C.;Schiff M.;Luggen M.;Becker J.C.;Aranda R.;Teng J.;Li T.;Schmidely N.;Le Bars M.;Dougados M. 04-01-2008. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatme Annals of the Rheumatic Diseases, 67 4, 547-554

Tugwell P.;Bombardier C.;Buchanan W.W.;Goldsmith C.;Grace E.;Bennett K.J.;Williams H.J.;Egger M.;Alarcon G.S.;Guttadauria M.;Yarboro C.;Polisson R.P.;Szydlo L.;Luggen M.E.;Billingsley L.M.;Ward J.R.;Marks C. 03-20-1990. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-ite Archives of Internal Medicine, 150 1, 59-62

Weinblatt M.;Schiff M.;Goldman A.;Kremer J.;Luggen M.;Li T.;Chen D.;Becker J. 02-01-2007. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis whil Annals of the Rheumatic Diseases, 66 2, 228-234

Luggen M. 02-01-2004. Trials Are Short, Disease Long: Measuring Drug Utility Beyond Clinical Trials Journal of Rheumatology, 31 2, 205-206

Farhey Y.;Luggen M. 01-01-1998. Seropositive, symmetric polyarthritis in a patient with poorly differentiated lung carcinoma: Carcin Arthritis and Rheumatism, 11 2, 146-149

Luggen M.;Belhorn L.;Evans T.;Fitzgerald O.;Spencer-Green G. 01-01-1995. The evolution of Raynaud's phenomenon: A longterm prospective study Journal of Rheumatology, 22 12, 2226-2232

Luggen M.;Hess E.;Gartside P. 01-01-1990. Measure of relative value of drugs in RA (I: Reply) Journal of Rheumatology, 17 7, 979

Williams H.J.;Furst D.E.;Dahl S.L.;Steen V.D.;Marks C.;Alpert E.J.;Henderson A.M.;Samuelson C.O.;Dreyfus J.N.;Weinstein A.;Maclaughlin E.J.;Alarcón G.S.;Kaplan S.B.;Guttadauria M.;Luggen M.E.;Reading J.C.;Egger M.J.;Ward J.R. 01-01-1985. Double?blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline fo Arthritis & Rheumatism, 28 3, 308-314